Collegium Pharmaceutical (COLL) Getting Somewhat Favorable News Coverage, Report Shows
Media stories about Collegium Pharmaceutical (NASDAQ:COLL) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 44.8456943068725 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities research analysts have weighed in on COLL shares. Piper Jaffray Companies set a $14.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, July 25th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, May 31st. ValuEngine upgraded shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Finally, HC Wainwright started coverage on shares of Collegium Pharmaceutical in a research report on Monday, September 11th. They set a “buy” rating and a $21.00 price target for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $20.67.
Shares of Collegium Pharmaceutical (NASDAQ COLL) traded down 3.97% on Monday, hitting $10.16. 229,481 shares of the company were exchanged. Collegium Pharmaceutical has a 52-week low of $9.97 and a 52-week high of $20.55. The firm’s market cap is $300.39 million. The company has a 50-day moving average price of $10.53 and a 200 day moving average price of $11.10.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative net margin of 1,319.39% and a negative return on equity of 93.73%. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $4.07 million. Analysts predict that Collegium Pharmaceutical will post ($3.00) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Collegium Pharmaceutical (COLL) Getting Somewhat Favorable News Coverage, Report Shows” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/18/collegium-pharmaceutical-coll-getting-somewhat-favorable-news-coverage-report-shows.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.